一种抗体及其药物偶联物和用途
By developing TF antibodies and ADCs with high binding affinity and specificity, the problem of interference with the coagulation system by existing drugs has been solved, achieving highly efficient targeted killing of TF-positive tumor cells and reducing side effects, thus providing a wider range of cancer treatment options.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- EVOPOINT BIOSCIENCES CO LTD
- Filing Date
- 2023-02-24
- Publication Date
- 2026-07-17
AI Technical Summary
While existing tissue factor (TF) antibody drugs have shown some efficacy in cancer treatment, they also interfere with the coagulation system, leading to side effects. There is a lack of antibody development targeting tumor cells that minimizes the impact of TF-mediated coagulation in normal tissues.
We present novel TF antibodies and antibody-drug conjugates (ADCs) derived from them. These antibodies exhibit high binding affinity and specificity, are rapidly endocytosed by tumor cells, and possess favorable physical properties. They demonstrate significant antitumor growth activity and good tolerability in animal models.
It achieves highly efficient targeted killing of TF-positive tumor cells, reduces the impact on the coagulation system of normal tissues, and provides a wider range of high-quality cancer treatment options.
Smart Images
Figure QLYQS_1 
Figure QLYQS_2 
Figure QLYQS_3